Despite many studies evaluating the role of perioperative EGFR–TKIs, the patient pool with stages IB–IIIA represents a very wide variety of cancers with inconstant prognosis [16], which may limit the application of these results to resected stage III EGFR-mutant adenocarcinoma. Here, EGFR is linked to adenocarcinoma.